Abstracts tagged "biologic drugs and clinical trials"

Abstract Number: 1884 • 2017 ACR/ARHP Annual Meeting
Mepolizumab for the Treatment of Patients with Eosinophilic Granulomatosis with Polyangiitis: Post-Hoc Results of a Phase III Randomized, Placebo-Controlled Trial
Jonathan Steinfeld¹, Eric S Bradford², Judith Brown³, Stephen Mallett⁴, Steven W Yancey² and Michael E Wechsler⁵, ¹Respiratory TAU & Flexible Discovery Unit, GSK, Philadelphia, PA, USA, Philadelphia, PA, ²Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA, Research Triangle Park, NC, ³Research and Development, Immuno-Inflammation TAU, GSK, Stockley Park West, Uxbridge, Middlesex, UK, Uxbridge, United Kingdom, ⁴Research & Development, Statistics, GSK, Stockley Park West, Uxbridge, Middlesex, UK, Uxbridge, United Kingdom, ⁵Department of Medicine,, National Jewish Health, Denver, CO
Background/Purpose: In a recent Phase III study (NCT02020889) in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) the anti-interleukin-5 monoclonal antibody mepolizumab showed significant benefit when…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].